KAINOS LABORATORIES, INC. KAINOS Laboratories, Inc. Stock
Equities
4556
JP3205650009
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,136 JPY | -0.26% |
|
-0.26% | +4.12% |
| Sales 2009 | 3.59B 22.84M | Sales 2010 | 4.22B 26.78M | Capitalization | 1.4B 8.91M |
|---|---|---|---|---|---|
| Net income 2009 | 168M 1.07M | Net income 2010 | 101M 642K | EV / Sales 2009 | 0.43 x |
| Net Debt 2009 | 893M 5.67M | Net Debt 2010 | 909M 5.77M | EV / Sales 2010 | 0.55 x |
| P/E ratio 2009 |
3.96
x | P/E ratio 2010 |
13.8
x | Employees | 133 |
| Yield 2009 |
2.68% | Yield 2010 |
2.38% | Free-Float | 38.54% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.26% | ||
| 1 week | -0.26% | ||
| 1 month | -5.49% | ||
| 3 months | -1.30% | ||
| 6 months | +5.58% | ||
| Current year | +4.12% |
1 week
1 129.00
1 158.00
1 month
1 120.001 245.00
Current year
1 055.001 289.00
1 year
1 000.001 289.00
3 years
929.001 675.00
5 years
681.002 047.00
10 years
453.002 047.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yukihiro Nagatsu
PSD | President | 64 | 82-03-31 |
Akihiko Suga
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sumio Shirai
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nobuo Nakano
BRD | Director/Board Member | 71 | - |
Yukihiro Nagatsu
PSD | President | 64 | 82-03-31 |
Tsukasa Hayashi
ADM | Chief Administrative Officer | 62 | 93-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,136 | -0.26% | 1,900 |
| 24-05-30 | 1,139 | -0.26% | 1,600 |
| 24-05-29 | 1,142 | -0.26% | 5,300 |
| 24-05-28 | 1,145 | +0.62% | 3,300 |
| 24-05-27 | 1,138 | -0.09% | 2,700 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotes
KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.
Calendar
2024-07-21
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +4.12% | 32.15M | |
| -3.43% | 12.45B | |
| -3.17% | 8.22B | |
| +6.11% | 5.72B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| -59.94% | 2.68B | |
| +11.23% | 2.68B | |
| -5.14% | 2.37B | |
| +18.91% | 2.06B |
- Stock Market
- Equities
- 4556 Stock
